Target intelligence / Profile preview

Type I collagen alpha-1 chain (COL1A1)

Target
COL1A1
Molecular classification
Fibrillar collagen, Structural protein, Extracellular matrix component
01

Overview

Type I collagen alpha-1 chain, encoded by the COL1A1 gene, is the principal protein subunit of type I collagen, the most abundant collagen in the human body and a major component of bone, skin, tendon, and other connective tissues[1][3][4][5]. The protein forms a triple-helical structure by assembling with another alpha-1 chain and one alpha-2 chain (COL1A2) to build fibrillar collagen networks that provide strength, rigidity, and elasticity to tissues[1][4][5]. Mutations in COL1A1 have been linked to a range of connective tissue disorders such as osteogenesis imperfecta, several forms of Ehlers-Danlos syndrome, and predispositions to osteoporosis and disc disease[1][3]. The intact protein is essential for normal skeletal development and connective tissue integrity, while its dysfunction results in tissue fragility and disease.

Other names
Collagen type I alpha-1 chainAlpha-1 type I collagenPro-alpha1(I) collagen chainCOL1A1
02

Mechanism of action

Indirect: Inhibition of bone resorption/matrix turnover (e.g., bisphosphonates decrease osteoclast activity reducing fracture risk in osteogenesis imperfecta) Indirect: Promotion of bone formation (e.g., teriparatide stimulates osteoblasts) Potential experimental: Reduction of fibrotic collagen synthesis (anti-fibrotic drugs)

03

Biological functions

Structural support of connective tissuesRigidity and elasticity of tissuesExtracellular matrix organizationBone mineralization
04

Disease associations

Osteogenesis imperfecta (brittle bone disease)Ehlers–Danlos syndrome (classical, vascular, and arthrochalasia types)OsteoporosisHernia predispositionDegenerative disc disease
05

Safety considerations

Mutations in COL1A1 cause widespread tissue fragility, high fracture risk, vascular rupture (in Ehlers-Danlos vascular type), and defective wound healing[1][3].Therapeutic inhibition may impair essential tissue integrity.
06

Interacting drugs

There are currently no approved therapies targeting COL1A1 directly, but bisphosphonates (e.g., alendronate) and teriparatide are used to manage downstream effects in conditions associated with COL1A1 mutations, such as osteoporosis and osteogenesis imperfecta[1][3]. Experimental agents such as anti-fibrotic drugs (pirfenidone, nintedanib) may affect collagen content in fibrotic diseases but do not target COL1A1 specifically.
07

Biomarkers

Mutant COL1A1 gene analysis for diagnosis of osteogenesis imperfecta and certain Ehlers-Danlos syndromes[1][3].Collagen-derived peptides in serum/urine (PICP, PINP) for monitoring bone turnover or fibrosis

Beyond the preview

Go deeper on Type I collagen alpha-1 chain (COL1A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Type I collagen alpha-1 chain (COL1A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call